Semaglutide (Novo Nordisk)

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for affordable access to approved medications. Based on an independent provider’s clinical decision, eligible Hims & Hers customers can now access Novo Nordisk treatments that can help them lose up to 20% of their body weight.2 Medication options include Wegovy® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injection and 1.5 mg, 4 mg, 9 mg, and 25 mg pills, with Wegovy® (semaglutide) 7.2 mg injection coming soon. Ozempic® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, and 2 mg injection pens, which are approved as treatments for Type 2 diabetes, will also be available for eligible patients based on individual clinical judgment. Ozempic is not FDA-approved for weight loss. Prices start as low as $149 a month.3 “Today we’re taking an important next step toward building a better model of healthcare that works for everyday people,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we’re thrilled to be working alongside Novo Nordisk to help more people feel their best and we’re excited to find more ways to collaborate across the industry.” “Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient,” said Dr. Craig Primack, SVP Weight Management at Hims & Hers. “As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We’re excited to see how our customers succeed as more innovative treatments become available.” The company is also introducing a new membership for weight loss, which will include comprehensive support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins, as well as peer support in the Hers Weight Loss community. Membership starts at $39 for the first month, $149 each month after.4 Medication costs are separate and may be covered under the customer’s HSA and FSA plan. All Hims & Hers subscribers have access to special savings. Customers will be educated on this expanding assortment of FDA-approved medications, and if determined clinically appropriate by their providers, will be given the opportunity to transition seamlessly to those medications. For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary. For more information, visit www.hims.com/weight-loss or www.forhers.com/weight-loss. About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com. Disclaimers This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, including their diversity, efficacy, pricing, dosages, and timing of availability; the quotes from our CEO and SVP, Weight Management; statements regarding the education of our customers on a broad assortment of FDA-approved medications and the potential transition to such medications; statements regarding our plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary and the expectation that such customer set will be limited; statements regarding future collaborations or expanded access to treatment options; and statements regarding the membership model, including pricing thereof and what it is expected to include. These statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the semaglutide offerings available on our platform (branded and compounded), and the related customer response; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options available on our platform; risks related to our international expansion efforts, including any pending or completed acquisitions, and the timing, integration and performance thereof; changes in the application, interpretation, and enforcement of healthcare, consumer protection or privacy laws or regulations applicable to our business; the timing, outcome or impact of this announcement on ongoing litigation, governmental actions or regulatory statements; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. In addition, at this time we cannot predict or estimate the impact any collaboration with Novo Nordisk and / or the impact any shift in our GLP-1 business may have on our future results, including revenue or EBITDA. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of March 26, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication. 1 Not available in all 50 states. Prescription required. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions. Wegovy® is a registered trademark of Novo Nordisk A/S. 2 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy® oral semaglutide 25 mg (64 weeks), about 1 in 3 taking Wegovy® injection 2.4 mg (68 weeks), and about 1 in 2 taking Wegovy® injection 7.2 mg (72 weeks) lost ≥20% of body weight, alongside diet and exercise. Average weight loss was approximately 14–19%. Individual results may vary. Stopping treatment may result in weight regain. 3 Membership required, fee not included, and billed separately. 4 Price includes membership fee only. Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership.